Autres langues Cosmo Pharmaceuticals N.V.

Actions

COPN

NL0011832936

Marché Fermé - Swiss Exchange Autres places de cotation 17:31:30 26/04/2024			Varia. 5j.	Varia. 1 janv.
71,6 ^CHF	-0,69%		+0,28%	+40,67%

26/04	Cosmo Pharmaceuticals N.V. annonce des changements exécutifs lors de la prochaine assemblée générale annuelle du 24 mai 2024	CI
25/04	Cosmo Pharmaceuticals nomme un nouveau CEO et un nouveau président	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024	26/04
Cosmo Pharmaceuticals Names New CEO, Chairman	25/04
Cosmo ernennt Giovanni Di Napoli zum neuen CEO - Della Chà wird VR-Präsident	25/04
Cosmo Announces Leadership Changes	25/04
Cosmo and Medtronic unveil the future of AI in GI, Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care	15/04
Cosmo treibt mit dem Partner Medtronic endoskopische Versorgung voran	12/04
Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care	12/04
Cosmo and Medtronic unveil the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care	12/04
Cosmo Pharmaceuticals N.V. Proposes Dividend Payment for 2024	20/03
Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2024 and Revenue Guidance for 2025	20/03
Cosmo Pharmaceuticals N : ESG Report 2023	20/03
Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share	20/03
Cosmo stellt trotz Gewinnrückgang verdoppelte Dividende in Aussicht	20/03
Cosmo Pharmaceuticals' FY23 Profit, Revenue Drops	20/03
Cosmo Pharmaceuticals N : reports excellent preliminary unaudited Full Year 2023 core financial results – Record guidance for 2024 – Doubles dividend to € 2.00 per share	20/03
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Cosmo erhält Zulassung für Winlevi in Australien	19/03
Cosmo Pharmaceuticals Partner Gets Regulatory Approval for Acne Treatment in Australia	19/03
Cosmo Pharmaceuticals Announces Approval of Winlevi(R) in Australia	19/03
Cosmo Pharmaceuticals N : announces approval of Winlevi® in Australia	19/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cosmo Pharmaceuticals N.V.

Actions

COPN

NL0011832936

Autres langues

Filtres